title: Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru.
abstract: It is well known that extranodal NK/T-cell lymphoma (NK/TCL) nasal type clusters in Asian countries. A large series of 78 cases of nasal NK/TCL from Peru is analyzed in the present study. Two histologic groups 1 (monomorphic) and 2 (polymorphic), were segregated according to the proportion of large cells (above and below 30%, respectively). Catalyzed signal amplification technique was performed for enhancement of immunohistochemistry reactivities. Epstein-Barr virus (EBV) sequences and types were investigated using polymerase chain reaction. Clinical characteristics, stage, outcome, and response to treatment were evaluated in both groups. Fourteen cases (18%) and 64 cases (82%) corresponded to groups 1 and 2, respectively. Except for nasal obstruction, more common in group 2, all other symptoms were similar in both groups. Local extension and staging were also comparable. Both groups showed CD3c+ CD2+ CD56+ CD3s- CD20- immunophenotype. All cases were positive for EBV. In this series type-2 EBV was found more frequent than type-1 EBV, contrarily to that observed in Asian series. However, about one-third of cases simultaneously harbored both viral types. Both groups received an average of 50-Gy dose of radiation therapy (RT), with or without chemotherapy. Complete therapeutic response was achieved in 89% of group 1 and in 74% of group 2, but this difference was not statistically significant. There were no significant differences between the groups regarding disease-free survival, failure-free survival, relapse, and overall survival. The overall survival, in both groups, was longer for patients treated with RT alone compared with those treated with combined RT therapy and chemotherapy. The present study has shown that dividing nasal NK/TCL in monomorphic and polymorphic variants, according to frequency of large cells, does not correlate with clinical and prognostic factors.
authors.affiliation: Department of Pathology, Instituto Nacional de Enfermedades Neoplasticas (I.N.E.N) Lima, Peru. cbarrionuevo@terra.com.pe
authors.forename: Carlos
authors.initials: C
authors.lastname: Barrionuevo
authors.forename: Mayer
authors.initials: M
authors.lastname: Zaharia
authors.forename: Marco T
authors.initials: MT
authors.lastname: Martinez
authors.forename: Luis
authors.initials: L
authors.lastname: Taxa
authors.forename: Oscar
authors.initials: O
authors.lastname: Misad
authors.forename: Alfredo
authors.initials: A
authors.lastname: Moscol
authors.forename: Gustavo
authors.initials: G
authors.lastname: Sarria
authors.forename: Ivonne
authors.initials: I
authors.lastname: Guerrero
authors.forename: Luis
authors.initials: L
authors.lastname: Casanova
authors.forename: Claudio
authors.initials: C
authors.lastname: Flores
authors.forename: Eduardo-Alfredo
authors.initials: EA
authors.lastname: Zevallos-Giampietri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000473:pathology* / Q000821:virology; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000175:diagnosis* / Q000821:virology; D010568:Peru / Q000453:epidemiology; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome